Important Information about Feraheme® (ferumoxytol) Injection
 

Feraheme is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).

The recommended dose of Feraheme is an initial 510 mg dose followed by a second 510 mg dose 3 to 8 days later, each dose infused over at least 15 minutes while the patient is in a reclined or semi-reclined position.

 
This website is intended for US healthcare professionals only.
In clinical trials, Feraheme raised mean Hgb 1 g/dL with only 1 g of IV iron.  Two 510-mg doses of Feraheme raised mean Hgb in adult patients with CKD who were NDD by 1.2 g/dL (± 1.3, SD; P ≤ 0.001) in Clinical Trial 1 and by 0.8 g/dL (± 1.2, SD; P ≤ 0.001) in Clinical Trial 2 vs baseline at day 35.

Evaluate patients' hematologic response (hemoglobin, ferritin, iron, and TSAT) at least 1 month following the second Feraheme administration.1

In clinical trials, Feraheme raised mean Hgb 1 g/dL with 1 g of IV iron1

Two 510-mg doses of Feraheme raised mean Hgb in adult patients with CKD who were NDD by 1.2 g/dL (± 1.3, SD; P ≤ 0.001) in Clinical Trial 1 and by 0.8 g/dL (± 1.2, SD; P ≤ 0.001) in Clinical Trial 2 vs baseline at day 35.

Important Safety Information
  • Fatal and serious hypersensitivity reactions including anaphylaxis, presenting with cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, or unresponsiveness, have occurred in patients receiving Feraheme. Other adverse reactions potentially associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing). These reactions have occurred following the first dose or subsequent doses in patients in whom a previous Feraheme dose was tolerated
Learn more
Proprietary polyglucose sorbitol carboxymethylether (PSC) coating engineered for targeted IV iron delivery. The PSC coating of Feraheme® (ferumoxytol) Injection is designed to help minimize the release of free iron by helping to isolate the bioactive iron core from plasma components until the iron-PSC complex enters the RES macrophages.
Proprietary polyglucose sorbitol carboxymethylether (PSC) coating engineered to help minimize the amount of freely circulating iron1

The PSC coating of Feraheme is designed to help minimize the release of free iron by isolating the bioactive iron core from plasma components until the iron-PSC complex enters the RES macrophages.

Important Safety Information
  • As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging studies for up to 3 months following the last Feraheme dose. Feraheme will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging
  • Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy, noting that lab assays may overestimate serum iron and transferrin bound iron values in the 24 hours following administration of Feraheme
Learn more
Administration flexibility with 2 infusions 3 to 8 days apart. Duration of delivery for diluted IV infusion is at least 15 minutes.

Duration of delivery for diluted IV infusion is at least 15 minutes.1

Two IV infusions with the schedule flexibility of 3 to 8 days apart1

Important Safety Information
  • Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated
  • Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products. Carefully consider the potential risks and benefits before administering Feraheme to these patients
  • Elderly patients with multiple or serious comorbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes
Learn more

CKD: chronic kidney disease; Hgb: hemoglobin; IV: intravenous; NDD: nondialysis dependent; PSC: polyglucose sorbitol carboxymethylether; RES: reticuloendothelial system; TSAT: transferrin saturation

Reference: 1. Feraheme [package insert]. Waltham, MA: AMAG Pharmaceuticals, Inc; Mar 2015.

Efficacy and safety in trials

In clinical trials, Feraheme raised mean Hgb 1 g/dL with only 1 g of IV iron.  Two 510-mg doses of Feraheme raised mean Hgb in adult patients with CKD who were NDD by 1.2 g/dL (± 1.3, SD; P ≤ 0.001) in Clinical Trial 1 and by 0.8 g/dL (± 1.2, SD; P ≤ 0.001) in Clinical Trial 2 vs baseline at day 35.

Click to read about clinical trials in which Feraheme raised mean Hgb 1 g/dL with 1 g of elemental IV iron1,*

In clinical trials Feraheme raised Hgb 1 g/dL with 1 g of IV iron
Evaluate patients’ hematologic response (hemoglobin, ferritin, iron, and TSAT) at least 1 month following the second Feraheme administration.
In clinical trials Feraheme raised Hgb 1 g/dL with 1 g of IV iron

Two 510-mg doses of Feraheme raised mean Hgb in adult patients with CKD who were NDD by 1.2 g/dL (± 1.3, SD; P ≤ 0.001) in Clinical Trial 1 and by 0.8 g/dL (± 1.2, SD; P ≤ 0.001) in Clinical Trial 2 vs baseline at day 35.1

Important Safety Information1

  • Fatal and serious hypersensitivity reactions including anaphylaxis, presenting with cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, or unresponsiveness, have occurred in patients receiving Feraheme. Other adverse reactions potentially associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing). These reactions have occurred following the first dose or subsequent doses in patients in whom a previous Feraheme dose was tolerated

CKD: chronic kidney disease; Hgb: hemoglobin; IV: intravenous; NDD: nondialysis dependent; TSAT: transferrin saturation

Mechanism of action

Proprietary polyglucose sorbitol carboxymethylether (PSC) coating engineered for targeted IV iron delivery. The PSC coating of Feraheme® (ferumoxytol) Injection is designed to help minimize the release of free iron by helping to isolate the bioactive iron core from plasma components until the iron-PSC complex enters the RES macrophages.

Click to see Feraheme’s proprietary polyglucose sorbitol carboxymethylether (PSC) coating engineered to help minimize the amount of freely circulating iron1

Proprietary polyglucose sorbitol carboxymethylether (PSC) coating engineered to help minimize the amount of freely circulating iron
  • The PSC coating of Feraheme is designed to help minimize the release of free iron by isolating the bioactive iron core from plasma components until the iron-PSC complex enters the RES macrophages
Important Safety Information
  • As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging studies for up to 3 months following the last Feraheme dose. Feraheme will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging
  • Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy, noting that lab assays may overestimate serum iron and transferrin bound iron values in the 24 hours following administration of Feraheme

PSC: polyglucose sorbitol carboxymethylether; RES: reticuloendothelial system

Feraheme - Mechanism of action

Dosing and administration

Administration flexibility with two IV injections 3 to 8 days apart

Click to learn more about the administration flexibility Feraheme offers with two IV injections or infusions 3 to 8 days apart1,†

Two IV infusions with the schedule flexibility of 3 to 8 days apart
Important Safety Information1
  • Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated
  • Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products. Carefully consider the potential risks and benefits before administering Feraheme to these patients
  • Elderly patients with multiple or serious comorbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes

IV: intravenous

Administration flexibility with 2 IV injections or infusions 3 to 8 days apart. Rate of delivery for IV injection is at least 17 seconds (1 mL/sec [30 mg/sec]). Rate of delivery for diluted IV infusion is at least 15 minutes.
Duration of delivery for diluted IV infusion is at least 15 minutes.1
Important Information about Feraheme® (ferumoxytol) Injection

Indication and Dosing

Feraheme is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).

The recommended dose of Feraheme is an initial 510 mg dose followed by a second 510 mg dose 3 to 8 days later, each dose infused over at least 15 minutes while the patient is in a reclined or semi-reclined position.

Important Safety Information

WARNING: RISK FOR SERIOUS HYPERSENSITIVITY/ANAPHYLAXIS REACTIONS

Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme.  Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest.

  • Only administer Feraheme when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.
  • Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following Feraheme infusion including monitoring of blood pressure and pulse during and after Feraheme administration.
  • Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated.

Contraindications

Feraheme is contraindicated in patients with:

  • Known hypersensitivity to Feraheme or any of its components
  • History of allergic reaction to any intravenous iron product

Warnings and Precautions

  • Fatal and serious hypersensitivity reactions including anaphylaxis, presenting with cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, or unresponsiveness have occurred in patients receiving Feraheme.  Other adverse reactions potentially associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing).  These reactions have occurred following the first dose or subsequent doses in patients in whom a previous Feraheme dose was tolerated.
  • Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products.  Carefully consider the potential risks and benefits before administering Feraheme to these patients.
  • Only administer Feraheme when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.  Closely observe patients for signs and symptoms of hypersensitivity including monitoring of blood pressure and pulse during and after Feraheme administration for at least 30 minutes and until clinically stable following completion of each infusion.
  • In clinical studies predominantly in patients with CKD, serious hypersensitivity reactions were reported in 0.2% (3/1,726) of subjects receiving Feraheme.  Other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing) were reported in 3.7% (63/1,726) of these subjects.  In other trials excluding patients with Stages 4 and 5 CKD, moderate to severe hypersensitivity reactions were reported in 2.6% (26/1,014) of patients treated with Feraheme.
  • Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes.
  • In the post-marketing experience, fatal and serious anaphylactic type reactions presenting with cardiac/ cardiorespiratory arrest, clinically significant hypotension, syncope, and unresponsiveness have been reported.  Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes.
  • Severe adverse reactions of clinically significant hypotension have been reported in the post-marketing experience. In clinical studies, hypotension was reported in 1.9% (33/1,726) of subjects, including three patients with serious hypotensive reactions. Monitor for signs and symptoms of hypotension following each Feraheme administration.
  • Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy, noting that lab assays may overestimate serum iron and transferrin bound iron values in the 24 hours following administration of Feraheme.
  • As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging studies for up to 3 months following the last Feraheme dose. Feraheme will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging.

Adverse Reactions

  • The most common adverse reactions (≥ 2%) following the administration of Feraheme are diarrhea, nausea, dizziness, hypotension, constipation, and peripheral edema.
  • In clinical trials, adverse reactions leading to treatment discontinuation and occurring in ≥ 2 Feraheme-treated patients included hypotension, infusion site swelling, increased serum ferritin level, chest pain, diarrhea, dizziness, ecchymosis, pruritus, chronic renal failure, and urticaria.
  • The following additional serious adverse reactions have been reported from the post-marketing experience with Feraheme:  tachycardia/rhythm abnormalities, angioedema, ischemic myocardial events, congestive heart failure, pulse absent, and cyanosis. These adverse reactions have usually occurred within 30 minutes after the administration of Feraheme. Reactions have occurred following the first dose or subsequent doses of Feraheme.
Reference: 1. Feraheme [package insert]. Waltham, MA: AMAG Pharmaceuticals, Inc; Mar 2015.